One Gel. Every Cell.
Endless Possibilities
A technology platform for high-sensitivity detection of targeted rare
cell populations directly from whole blood, designed for clinical and
translational applications.
One Gel. Every Cell.
Endless
Possibilities
A technology platform for high-sensitivity detection of targeted rare cell populations directly from whole blood, designed for clinical and translational applications.
01
Patented Hydrogel Matrix
A transparent 3D matrix engineered for whole blood capture.
01
Patented Hydrogel Matrix
A transparent 3D matrix engineered for whole blood capture.
A volumetric, optically clear hydrogel that immobilizes cells directly from whole blood, preserving morphology and enabling consistent downstream imaging.
02
Ultra-High Sensitivity
Detection
Detection
Reliable detection of rare cell events across millions of cells.
02
Ultra-High Sensitivity
Detection
Reliable detection of rare cell events across millions of cells.
In situ capture preserves cellular structure and spatial context, enabling detection of targeted rare cell populations without enrichment bias.
03
Rapid, High-Throughput
Workflow
Workflow
From blood draw to imageable specimen.
03
Rapid, High-Throughput
Workflow
Workflow
From blood draw to imageable specimen.
A streamlined, device-free workflow with minimal hands-on time, designed for consistent, scalable processing across samples.
04
Built for Clinical &
Research Applications
One platform. Multiple applications.
04
Built for Clinical &
Research Applications
One platform. Multiple applications.
Supports cancer surveillance, treatment monitoring, and drug development through reliable detection of defined cell populations.
OUR MISSION
The cellular future of liquid biopsy starts in one gel, transforming hidden rare cells into clinical foresight.
NET-Based Clinical
& Translational Profiling
01 Cancer Progression & Therapy-Response Profiling
IN ONCOLOGYNET signatures can indicate immune evasion, pre-metastatic niche formation, metastatic seeding, and poor response to immune checkpoint therapy.ICI response / Metastatic risk / Antitumor immunity
02 Immune-Mediated Inflammation Profiling
IN IMMUNE INFLAMMATIONNET-derived DNA and proteins may expose autoantigens, amplify type I IFN/cytokine signaling, and sustain tissue-damaging inflammatory loops.SLE activity / Rheumatoid synovitis / Sterile inflammation
03 Thrombosis & Immunothrombosis Profiling
IN THROMBOSIS BIOLOGYNET burden can highlight platelet–fibrin scaffolding, venous clot propagation, and thrombolysis-resistant thrombi across vascular diseases.Coagulation scaffold / DVT progression / Stroke thrombolysis resistance
04 Reproductive Failure & Pregnancy-Loss Profiling
IN REPRODUCTIVE MED NETsNET signatures may reveal inflammatory pelvic niches, impaired embryo–endometrial tolerance, and immune-thrombotic injury linked to infertility, implantation failure, and pregnancy loss.Endometriosis-associated infertility / Implantation failure / Pregnancy-loss risk
01 Cancer Progression & Therapy-Response Profiling IN ONCOLOGY
Cancer Progression & Therapy-Response Profiling
NET signatures can indicate immune evasion, metastatic niche formation, tumor-cell trapping, and poor response to immune checkpoint therapy.ICI response / Metastatic risk / Antitumor immunity
02 Immune-Mediated Inflammation Profiling IN IMMUNE INFLAMMATION
Immune-Mediated Inflammation Profiling
NET-derived DNA and proteins may expose autoantigens, amplify type I IFN/cytokine signaling, and sustain tissue-damaging inflammatory loops.SLE activity / Rheumatoid synovitis / Sterile inflammation
03 Thrombosis & Immunothrombosis Profiling IN THROMBOSIS BIOLOGY
Thrombosis & Immunothrombosis Profiling
NET burden can highlight platelet–fibrin scaffolding, venous clot propagation, and thrombolysis-resistant thrombi across vascular diseases.Coagulation scaffold / DVT progression / Stroke thrombolysis resistance
04 Reproductive Failure & Pregnancy-Loss Profiling IN REPRODUCTIVE MED NETs
Reproductive Failure & Pregnancy-Loss Profiling
NET signatures may reveal inflammatory pelvic niches, impaired embryo–endometrial tolerance, and immune-thrombotic injury linked to infertility, implantation failure, and pregnancy loss.Endometriosis-associated infertility / Implantation failure / Pregnancy-loss risk
Driven by
clinical utility.
01 Post-Surgical MRD Surveillance
IN CLINICAL VALIDATIONLongitudinal residual cell tracking to monitor recurrence risk during the imaging- silent interval.3 Active cancer indications / 2+ Collaborating institutions
02 Adjuvant Therapy Monitoring
UNDER EVALUATION
Real-time treatment efficacy assessment, enabling therapeutic adjustments prior to radiographic scans.
CDx — Companion diagnostic potential | MRD — Dynamic monitoring framework
03 TME & Immunotherapy Profiling
UNDER EVALUATION
NETs and tumor microenvironment marker integration to predict checkpoint inhibitor response.
NETs — Immune evasion marker | TME — Tumor microenvironment analysis
04 Multi-Omics Integration
UNDER EVALUATION
Combining cellular signals, ctDNA, and exosomes to maximize diagnostic precision.
4 Biomarker dimensions | Extensible analytic framework
01 Post-Surgical MRD Surveillance IN CLINICAL VALIDATION
Post-Surgical MRD Surveillance
Longitudinal residual cell tracking to monitor recurrence risk during the imaging- silent interval.3 Active cancer indications / 2+ Collaborating institutions
02 Adjuvant Therapy Monitoring UNDER EVALUATION
Adjuvant Therapy Monitoring
Real-time treatment efficacy assessment, enabling therapeutic adjustments prior to radiographic scans.CDx — Companion diagnostic potential | MRD — Dynamic monitoring framework
03 TME & Immunotherapy Profiling UNDER EVALUATION
TME & Immunotherapy Profiling
NETs and tumor microenvironment marker integration to predict checkpoint inhibitor response.NETs — Immune evasion marker | TME — Tumor microenvironment analysis
04 Multi-Omics Integration UNDER EVALUATION
Multi-Omics Integration
Combining cellular signals, ctDNA, and exosomes to maximize diagnostic precision.4 Biomarker dimensions | Extensible analytic framework
- All listed application areas are at the research and evaluation stage. Some have not yet entered clinical validation and do not constitute medical diagnostic recommendations or clinical application commitments.
- The ImmunoGel platform has not received regulatory clearance from any competent authority for in vitro diagnostic use.
Built for clinical care.
Designed for bio-discovery.
ImmunoGel bridges rare-cell biology to clinical care,
translational research, and therapeutic development.
Partner With Us
Advance Patient Care.
Integrate blood-based MRD monitoring into your practice to proactively guide post-surgical care.
For Clinicians
Accelerate
Discovery.
Partner with us to generate multi-center validation data across solid tumor indications.
For Investigators
Empower CDx Development.
Utilize our reproducible ImmunoGel workflow to power companion diagnostic (CDx) development in your clinical trials.
For Biopharma
SOURCES
- Based on the WHO Global Cancer Observatory (GLOBOCAN 2022), approximately 19.96 million new cancer cases were diagnosed worldwide in 2022, displayed on this site as 19M+. This figure covers all cancer types at initial diagnosis and continues to grow with aging populations. Source: Bray et al., CA: A Cancer Journal for Clinicians, 2024.
- Post-surgical recurrence rate: pooled estimates across major solid tumor types (colorectal, lung, liver, etc.) indicate approximately 30% of patients who undergo curative-intent resection will experience local or distant relapse within five years. See Haller et al., Journal of Clinical Oncology, 2005 (CRC adjuvant therapy cohort, ~30% recurrence); Siegel et al., CA Cancer J Clin, 2024. Rates vary by cancer type and stage.
- Post-relapse mortality: per SEER data (2014-2020), five-year relative survival for distant-stage (Stage IV) solid tumors is approximately 20-35%, corresponding to a five-year mortality rate of 65-80%. The 65% figure displayed on this site represents a conservative lower-bound estimate across major cancer types. Source:Cancer Facts & Figures 2024, American Cancer Society.
- Distant-stage survival (3-30%): Liver cancer (3.5%) and ovarian cancer (30.8%) distant-stage five-year relative survival rates, based on NCI Surveillance, Epidemiology, and End Results (SEER) Program data. Colorectal cancer (14%) distant-stage five-year survival rate is sourced from the American Cancer Society, Cancer Facts & Figures 2024.
Localized-stage survival (>=90%): Colorectal cancer (91%) and ovarian cancer (93%) localized five-year relative survival rates, defined as tumor confined to the primary site with no regional or distant spread, sourced from the American Cancer Society & NCI SEER Program. All figures are population-level statistical estimates; individual prognosis is influenced by multiple clinical factors.
- Based on the WHO Global Cancer Observatory (GLOBOCAN 2022), approximately 19.96 million new cancer cases were diagnosed worldwide in 2022, displayed on this site as 19M+. This figure covers all cancer types at initial diagnosis and continues to grow with aging populations. Source: Bray et al., CA: A Cancer Journal for Clinicians, 2024.
- Post-surgical recurrence rate: pooled estimates across major solid tumor types (colorectal, lung, liver, etc.) indicate approximately 30% of patients who undergo curative-intent resection will experience local or distant relapse within five years. See Haller et al., Journal of Clinical Oncology, 2005 (CRC adjuvant therapy cohort, ~30% recurrence); Siegel et al., CA Cancer J Clin, 2024. Rates vary by cancer type and stage.
- Post-relapse mortality: per SEER data (2014-2020), five-year relative survival for distant-stage (Stage IV) solid tumors is approximately 20-35%, corresponding to a five-year mortality rate of 65-80%. The 65% figure displayed on this site represents a conservative lower-bound estimate across major cancer types. Source:Cancer Facts & Figures 2024, American Cancer Society.
- Distant-stage survival (3-30%): Liver cancer (3.5%) and ovarian cancer (30.8%) distant-stage five-year relative survival rates, based on NCI Surveillance, Epidemiology, and End Results (SEER) Program data. Colorectal cancer (14%) distant-stage five-year survival rate is sourced from the American Cancer Society, Cancer Facts & Figures 2024.
Localized-stage survival (>=90%): Colorectal cancer (91%) and ovarian cancer (93%) localized five-year relative survival rates, defined as tumor confined to the primary site with no regional or distant spread, sourced from the American Cancer Society & NCI SEER Program. All figures are population-level statistical estimates; individual prognosis is influenced by multiple clinical factors.